The US Food and Drug Administration's Pharmacy Compounding Advisory Committee will meet Thursday and Friday to determine whether seven peptides can be produced by licensed compounding pharmacies for patients with prescriptions. The FDA has questioned supporting evidence for these short amino acid chains that occur naturally and regulate biological processes. Ozempic and Wegovy are approved peptide-based medicines that have gained widespread recognition.